Mission First-in-Class Research

Anagin is developing first-in-class novel targeted therapies for addressing pathologies associated with disrupted synaptic plasticity in the central nervous system leading to psychiatric diseases.  Such diseases include, but are not limited to, Post Traumatic Stress Disorder (PTSD), Traumatic Brain Injury (TBI), Depression, Neuropathic Pain, Alzheimer’s disease and Parkinson’s disease.

Research and Development
First-in-Class Research
Play Video